Comparison Of The Curative Efficacy Between TA And Bevacizumab For Macular Edema Induced By Branch Retinal Vein Occlusion

Objective:To evaluate the efficacy and safety of intravitreal Triamcinolone acetonide andBevacizumab for treatment of macular edema secondary to branch retinal veinocclusion(BRVO), guiding clinical therapy.Methods:Retrospective analysis of the patients in January2012-June2013at the FirstAffiliated Hospital of Zhengzhou University, branch retinal vein occlusion due tomacular edema accepted triamcinolone acetonide (TA) or bevacizumab treatment,atotal of85eyes of85people, the intravitreal injection includes in40to accept TA2mg (0.05ml),45to accept Bevacizumab1.25mg (0.05ml). Divided into TA groupand Bevacizumab group. Recording the number of injections within six months,preoperative and postoperative best corrected visual acuity(BCVA), intraocularpressure, lens, central macular thickness (CMT) and other changes within6months.Results:①The visual acuity of patient who accept treatment at6months was significantlyimproved in both groups, TA group accounted for62.5%, Bevacizumab groupaccounted for66.7%;②t heboth group average postoperative CMT is significantly decreased than preoprative, compared with preoperative have significant statisticalsignificance(P＞0.05);③The TA group intraocular pressure increased afterpostoperative l week, and mean IOP was still higher than the preoperative IOP atbaseline6months, the comparative difference was significant statistical significance（P＜0.05）,the comparative difference of Bevacizumab group IOP was no statisticalsignificance between before and after treatment (P＞0.05),mean IOP in TA groupwas higher than Bevacizumab group on the same time point aftertreatment;④p ostoperation2-6months, TA group,17cases (42.5%),9cases (22.5%),3cases (7.5%), Bevacizumab group,29cases (64.4%),17cases (37.8%),5cases(11.1%) were injected2,3,4times, follow-up review after being repeated injections,macular edema of patients subsided, visual acuity recovered, the second injection ratecomparetive between the two groups was statistically significant（P＜0.05）;⑤TAgroup IOP of14cases patient had severely increased (≥30mmHg),2cases ofsecondary glaucoma, the rate of ocular complication was40.0%(16/40),Bevacizumab group corneal epithelial sheet exfoliation of2cases,4cases smallpieces subconjunctival hemorrhage at the intraocular injection site occurred,incidence of adverse reactions was13.3%(6/45), compared with incidence of ocularcomplications groups there was a significant statistical significance（P＜0.01）;⑥t here were no serious complications in the two groupsof infectiousendophthalmitis, vitreous hemorrhage, retinal detachment, choroidal detachment.Conclusions:TA and Bevacizumab intravitreal injection treatment of macular edema in branchretinal vein occlusion can reduce macular retinal thickness and improve vision, butrepeated injections are required. TA has more complications,bevacizumab has fewercomplications, good security.